Helio Genomics announced that Chief Medical Advisor Dr. Richard Van Etten will present HelioLiver’s superior performance over ultrasound for early HCC detection at the 2024 AASLD Annual Meeting in San Diego.
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Helio Genomics (“Helio” or “the Company”) today announced an upcoming presentation by its Chief Medical Advisor, Dr. Richard Van Etten, MD, PhD, at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting in San Diego, California.
- Title: “Shaping the Future: Clinical Validation of a Multi-Analyte Blood Test for Early HCC Detection”
- Date and Time: November 18, 2024; 1:30–2:00 PM PST
- Location: San Diego Convention Center, Booth #1730 in Exhibit Hall B — TLM Theater 1
HelioLiver, an advanced blood test for early HCC detection, has shown superior performance over ultrasound, especially in identifying HCC lesions ≤ 3 cm. The presentation dives into these findings and their impact on the liver cancer landscape.
“We are thrilled to have one of the most prestigious, world-class speakers present groundbreaking data from the CLiMB trial at the AASLD annual meeting. Dr. Van Etten’s presentation of our multi-analyte blood test for early cancer detection underscores the importance of having an improved, blood-based diagnostic test for patients who are at high risk for HCC.”
“Helio Genomics is at the forefront of diagnostic technologies for early cancer detection, as evident by the ongoing positive outcomes observed with their HelioLiver test. Reliable early detection for HCC is lacking, and the CLiMB trial results demonstrate that Helio’s diagnostic test has tremendous potential for addressing a large, unmet medical need.”
About Richard A. Van Etten, MD, PhD
Richard A. Van Etten, MD, PhD, is Chief Medical Advisor for Helio Genomics and Director of the Chao Family Comprehensive Cancer Center at UCI Health. A board-certified, fellowship-trained hematologist and oncologist, he leads a team of more than 250 physicians and scientists conducting cancer research at UC Irvine. He earned his MD and a PhD in biophysics from the Stanford University School of Medicine, completed his residency and hematology fellowship at Harvard Medical School and Brigham & Women’s Hospital, and was a visiting scientist in the lab of Nobel laureate David Baltimore at MIT’s Whitehead Institute. He is the author of more than 150 scientific articles, reviews and book chapters.
Upcoming Events Hosted by Helio Genomics
An exclusive evening of networking and cocktails with company management at AASLD on Monday, November 18, 2024 at 5:00 PM PT, where Dr. Van Etten will discuss the Company’s CLiMB trial, recent data on its methylation model for tumor aggressiveness, and other pipeline products for liver cancer.
A virtual KOL event on Monday, November 25, 2024 at 10:00 AM ET to discuss recent CLiMB trial data and the methylation model score in patients with HCC, featuring Dr. Richard Van Etten, followed by a live Q&A.
Recent News
Helio recently presented a poster on its collaboration with Ochsner Health at the 2024 San Antonio Liver Cancer Symposium, where the abstract was awarded one of the top three by the Symposium Committee. Read the full press release.
About HelioLiver
HelioLiver is a multi-analyte blood test that analyzes cfDNA methylation patterns, serum protein markers and demographic information to detect early-stage HCC for patients at risk due to liver cirrhosis or Hepatitis B. HelioLiver achieved superior sensitivity and non-inferior specificity compared to ultrasound, as demonstrated by the ENCORE and CLiMB clinical trials. It has received a Category I CPT PLA code from the American Medical Association, effective October 1, 2022. Based on the CLiMB trial, Helio submitted its PMA application for HelioLiver to the FDA in the second quarter of 2024 for authorization as a Class III medical device; prior to FDA approval, HelioLiver is available in the U.S. in a CLIA laboratory as a laboratory developed test (LDT).
About Helio Genomics
Helio Genomics, founded in 2016 and headquartered in Irvine, CA, is a commercial-stage, AI-driven diagnostics platform company focused on developing pioneering tests for early cancer detection, precision oncology, recurrence and treatment monitoring, using liquid biopsy and DNA methylation analysis.
Investor Contact
Jeremy Feffer
Managing Director, LifeSci Advisors
jfeffer@lifesciadvisors.com
SOURCE Helio Genomics via GLOBE NEWSWIRE.